Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Ведение пациентов с болевыми синдромами на фоне COVID-19

Full Text:

Abstract

The disease caused by COVID-19 is multi-organ and involves almost all organs and systems. Myalgias and arthralgias and back pain are common symptoms of COVID-19 and can be observed both at the onset of the disease and in the postcoid period. The cause of muscle and joint damage is both systemic inflammation and direct damage by the virus. Musculoskeletal pain can be observed both at the onset of the disease and in the post-COVID period. Traditionally, musculoskeletal pain is treated with NSAIDs, however, the use of this group of drugs in patients with COVID-19 requires caution as to comorbidity and possible complications of viral infection. The article discusses clinical variants and pathogenetic mechanisms of damage of joints and muscles against the background of COVID-19 infection as well as treatment tactics for patients with skeletal muscle syndrome.

About the Authors

L. Т. Аkhmedzhanova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine 

11, Rossolimo St., Build. 1, Moscow 119021



T. M. Ostroumova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine 

11, Rossolimo St., Build. 1, Moscow 119021



O. A. Solokha
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine; A.Ya. Kozhevnikov Clinic of Nervous System Diseases

11, Rossolimo St., Build. 1, Moscow 119021



References

1. Karaarslan F, Demircioğlu Güneri F, Kardeş S. Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews. Rheumatol Int. 2021 Jul;41(7):1263-1271. doi: 10.1007/s00296-021-04882-8

2. Jiang F, Yang WL, Wang JW et al. Pain during and after coronavirus disease 2019: Chinese perspectives. Pain Rep. 2021;6(1):e931. Published 2021 May 10. doi:10.1097/PR9.0000000000000931

3. Zhou Y., Han T., Chen J et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin. Transl. Sci. 2020;13:1077–1086. doi: 10.1111/cts.12805

4. Drożdżal, S., Rosik, J., Lechowicz, K., et al. COVID-19: pain management in patients with SARS-CoV-2 infection-molecular mechanisms, challenges, and perspectives. Brain Sci. 2020;10:465. doi: 10.3390/brainsci10070465

5. Abdullahi A, Candan SA, Abba MA, et al. Neurological and Musculoskeletal Features of COVID-19: A Systematic Review and Meta-Analysis. Front Neurol. 2020 Jun 26;11:687. doi: 10.3389/fneur.2020.00687

6. Sadiye Murat , Bilinc Dogruoz Karatekin, Afitap Icagasioglu, Celal Ulasoglu. Clinical presentations of pain in patients with COVID-19 infection Ir J Med Sci.. 2021 Aug;190(3):913-917. doi: 10.1007/s11845-020-02433-x.

7. Li LQ, Huang T, Wang YQ et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-583. doi: 10.1002/jmv.25757

8. Fernández-de-Las-Peñas C, Rodríguez-Jiménez J, Fuensalida-Novo S et al. Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study. Pain. 2021 Apr 8. doi: 10.1097/j.pain.0000000000002306

9. Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244

10. Weng LM, Su X, Wang XQ. Pain Symptoms in Patients with Coronavirus Disease (COVID-19): A Literature Review. J Pain Res. 2021 Jan 26;14:147-159. doi: 10.2147/JPR.S269206

11. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China. JAMA Neurol 2020. https://doi.org/10.1001/jamaneurol.2020.1127

12. Joob B., Wiwanitkit V. Arthralgia as an initial presentation of COVID-19: Observation. Rheumatol. Int. 2020;40:823. doi: 10.1007/s00296-020-04561-0.

13. Chen T., Dai Z., Mo P. et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: A single-centered, retrospective study. J. Gerontol. A Biol. Sci. Med. Sci. 2020;75:1788–1795. doi: 10.1093/gerona/glaa089

14. Mo P., Xing Y., Xiao Y. et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin. Infect. Dis. 2020;270:ciaa270. doi: 10.1093/cid/ciaa270

15. Vasiliadis AV, Tsatlidou M, Metaxiotis D et al. Non-Respiratory Symptoms of Patients Infected with SARS-CoV-2 (Coronavirus Disease 2019): Lessons from Their Initial Presentation at the Hospital. Medicina (Kaunas). 2021;57(4):344. Published 2021 Apr 2. doi:10.3390/medicina57040344

16. Mokuda S., Tokunaga T., Masumoto J., Sugiyama E. Angiotensin-converting Enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin 6 through STAT3 signaling in synovial tissues. J Rheumatol. 2020;47(10):1593–1595. doi: 10.3899/jrheum.200547

17. Sisó-Almirall A, Brito-Zerón P, Conangla Ferrín L, et al. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health. 2021;18(8):4350. Published 2021 Apr 20. doi:10.3390/ijerph18084350

18. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021 May 22:1-18. doi: 10.1080/23744235.2021.1924397.

19. Grech S, Borg JN, Cuschieri S. Back pain: An aftermath of Covid-19 pandemic? A Malta perspective. Musculoskeletal Care. 2021 Jun 6:10.1002/msc.1574. doi: 10.1002/msc.1574

20. Arca M, Dönmezdil S, Durmaz ED. The effect of the COVID-19 Pandemic on anxiety, depression, and musculoskeletal system complaints in healthcare workers. Work. 2021;69(1):47-54. doi: 10.3233/WOR-205014

21. Каратеев АМ., Лила ЛИ., Алексеева ЛИ. Ведение пациентов с заболеваниями скелетно-мышечной системы в период пандемии COVID-19.

22. Wong AY, MacKenna B, Morton CE et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an Open SAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021 Jul;80(7):943-951. doi: 10.1136/annrheumdis-2020-219517

23. Thomas M Drake , Cameron J Fairfield , Riinu Pius, Stephen R Knight. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study Lancet Rheumatol 2021 Jul;3(7):e498-e506. doi: 10.1016/S2665-9913(21)00104-1

24. Robb C.T., Goepp M., Rossi A.G., Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177(21): 4899–920. doi: 10.1111/bph.15206.

25. Ren Mao 1 , Yun Qiu 2 , Jin-Shen He 2 , Jin-Yu Tan 2 , Xue-Hua Li 3 Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678. doi: 10.1016/S2468-1253(20)30126-6

26. Wei-Ting Chang, Han Siong Toh, Chia-Te Liao, Wen-Liang Yu. Cardiac Involvement of COVID-19: A Comprehensive Review Am J Med Sci.. 2021 Jan;361(1):14-22. doi:10.1016/j.amjms.2020.10.002.

27. Xiaopeng Yang 1 , Shasha Tian 1 , Hui Guo.Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis Int Immunopharmacol.. 2021.Jan;90:107159. doi: 10.1016/j.intimp.2020.107159

28. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78

29. Patel P.B., Patel T.K. Efficacy and safety of aceclofenac in osteoarthritis: а meta-analysis of randomized controlled trials// Eur. J. Rheumatol. 2017. Vol. 4. № 1. P. 11–18. doi: 10.5152/eurjrheum.2017.160080.

30. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12): 1127-46. doi: 10.2165/11633470000000000-00000

31. Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746.

32. Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362.

33. Karateev AE, Tsurgan AV. Aceclofenac:the experience of Russian studies. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94 (In Russ.) doi: 10.14412/1996-7012-2017-4-89-94

34. Karateev AE. Evaluation of the population safety of nonsteroidal anti-inflammatory drugs in the framework of the PanEuropean SOS program: focus on aceclofenac. Nevrologiya,neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020:12 (2):109-113. DOI:10.14412/2074-2711-2020-2-109-113.

35. Karateev А.Е,. Pogozheva E.Yu., Filatova Е.S. at al. Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy). Terapevticheskiy Archiv.2018. (6):65-74. doi.org/10.26442/terarkh201890665-73.

36. Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C., Annane D., Azevedo L.C.P., Berwanger O., Cavalcanti A.B. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. 2020;324:1330–1341. doi:10.1001/jama.2020.17023.

37. Abdel Shaheed C., Maher C. G., Williams K. A., McLachlan, A. J. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. European Journal of Pain.2016;21(2):228–237. doi:10.1002/ejp.907

38. Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP).Nevrologiya, Neiropsikhiatriya, Psikhosomatika Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4-11 (In Russ.). doi: 10.14412/2074-2711-2018-2-4-11

39. Parfenov V.A., Yakhno N.N., Davydov O.S. et al. Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2S):7-16. https://doi.org/10.14412/2074-2711-2019-2S-7-16

40. Karasavvidis T., Hirschmann M.T., Kort N.P. et al. Home-based management of knee osteoarthritis during COVID-19 pandemic: literature review and evidence-based recommendations. J Exp Orthop. 2020; 7(1): 52. doi: 10.1186/s40634-020-00271-5.

41. Mazzei D., Ademola A., Abbott J. et al. Are education, exercise and diet interventions a cost-effective treatment to manage hip and knee osteoarthritis? A systematic review. Osteoarthritis Cartilage. 2020; S1063-4584(20)31165-1. doi: 10.1016/j.joca.2020.10.002


For citation:


Аkhmedzhanova L.Т., Ostroumova T.M., Solokha O.A. Ведение пациентов с болевыми синдромами на фоне COVID-19. Neurology, Neuropsychiatry, Psychosomatics. 0;. (In Russ.)

Views: 34


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)